Dr. Anna Bukiya’s PhD laboratory focuses on lipid modulation of ion channel function in excitable tissues and sensitivity to drugs. Dr. Bukiya’s work has been consistently funded by the NIH and private foundations, and she has published 43 original research articles, authored or co-authored 10 reviews, and 9 book chapters. Dr. Bukiya also co-edited two books and served as a sole editor on one book, all focused on the role of lipids in modulating protein function during normal physiology and pathological conditions. The Bukiya laboratory utilizes computational modelling of cholesterol-protein interactions, biochemical and fluorescence microscopy-based quantification of cellular cholesterol levels, rat models of high-cholesterol diet, and statin use to control cholesterol levels in vivo. Dr. Bukiya is a current member of several societies, including Biophysical Society, International Drug Abuse Research Society, and American Society for Pharmacology and Experimental Therapeutics. Dr. Alex Dopico MD, PhD received his M.D. from the University of Buenos Aires, specializing in arterial hypertension. Following his Ph.D. in Pharmacology, he conducted postdoctoral training at UMass Worcester focusing on the regulation of ion channels by lipids and alcohols. Over two decades, the Dopico laboratory has addressed ion channel regulation by a wide variety of lipids, including fatty acids, leukotrienes, glycerophospholipids, PIP2 and related phosphoinositides, bile acids and other cholanes, pregnenolone and cholesterol itself. His studies on alcohol and toluene aim at determining the relative contribution of ion channels and their surrounding membrane lipids to drug action, addressing the impact of drug action on organ function, with a focus on cerebral arteries. In 2009, he received a Merit Award from NIAAA for his work on ethanol actions on slo1 channels. He is member of the National Advisory Committee on Alcohol Abuse & Alcoholism.

Select Guide Rating

• Part 1. Cholesterol Chemistry and Cell Function1. Cholesterol chemistry, and laboratory synthesisHélio M.T. Albuquerque, Clementina M.M. Santos, and Artur M.S. Silva2. Molecular evolution of cholesterol and other higher sterols in relation to membrane structureOle G. Mouritsen3. Role of cholesterol in maintaining the physical properties of the plasma membraneWitold K. Subczynski, Marta Pasenkiewicz-Gierula, Justyna Widomska, and Natalia Stein4. The fundamental interaction of cholesterol with lipid membranes: The umbrella modelJuyang Huang5. Model peptides and cholesterolIstván P. Sugár and Parkson Lee-Gau Chong6. Cholesterol and ceramide: An unlikely pairAritz B. García-Arribas, Alicia Alonso, and Félix M. Goñi7. Cholesterol-recognizing amino acid consensus motifs in transmembrane proteins: Comparative analysis of in silico studies and structural dataFodil Azzaz, Henri Chahinian, Nouara Yahi, Coralie Di Scala, Carlos J. Baier, Francisco J. Barrantes, and Jacques Fantini8. Effects of cholesterol on the GPCR AT1 receptor and its interplay with AT1 antagonistsS. Kiriakidi, Z. Cournia, and T. Mavromoustakos9. Principles of cholesterol regulation of ion channelsQiu-Xing Jiang and Irena Levitan10. Fluorescent probes for microscopy visualization of cholesterol topography and dynamics in membranesFrancisco J. Barrantes11. Cholesterol transport in blood, lipoproteins, and cholesterol metabolismMark T Mc Auley and Amy E Morgan12. Common laboratory research methods for detection and quantification of cholesterolAnna N. Bukiya, Hanxuan Li, Steven Mysiewicz, and Wei LiPart 2. Cholesterol Homeostasis and its disruption14. Diet-induced hypercholesterolemia in small laboratory animal modelsTina Herfel15. Nutrition and cholesterol metabolismGhada A. Soliman16. Cholesterol and early developmentIsabella Ellinger and Waranya Chatuphonprasert17. Clinical and biochemical diagnostic methods: What do blood lipid levels tell us?Marshall B. Elam18. Familial hypobetalipoproteinemia and abetalipoproteinemiaFrancine K. Welty19. Critical illness and cholesterol levelsZdenek Zadak20. Familial hypercholesterolemiaShifa Jebari-Benslaiman, Unai Galicia-Garcia, Asier Larrea-Sebal, Kepa B. Uribe, Cesar Martin, and Asier Benito-Vicente21. Niemann-Pic type C disease (NPC)Agnieszka Ługowska22. Rare monogenic disorders of cholesterol metabolismMalgorzata Bednarska-Makaruk and Agnieszka Ługowska23. Secondary (acquired) hypercholesterolemiaArrigo F.G. Cicero and Ivan R. Cincione24. Blood lipids and molecular pathways of atherogenesisRicardo Stein, Filipe Ferrari, and Vítor M. Martins25. Lysosomal acid lipase: Roles in rare deficiency diseases, myeloid cell biology, innate immunity, and common neutral lipid diseasesGregory A. Grabowski and Hong Du26. Cholesterol and pathogensTatiana M. Clemente and Stacey D. Gilk27. Involvement of cholesterol and ß-amyloid in the initiation and progression of Alzheimer’s diseaseLuis G. Aguayo, Jorge P. Roa, Carlos F. Burgos, and Juliana  Gonzalez-Sanmiguel28. Cholesterol and alcoholAndrew S. Bell, Emma M. O’Connell, and Falk W. LohoffPart 3. Pharmacological Considerations and Perspectives29. Cholesterol stiffening of lipid membranes and drug interactions: Insights from neutron spin echo and deuterium NMR spectroscopySudipta Gupta, Fathima T. Doole, Teshani Kumarage, Milka Doktorova, George Khelashvili, Rana Ashkar, and Michael F. Brown30. Cholesterol in drug delivery systemsDanRong Hu and ZhiYong Qian31. Modification of vascular receptor pharmacology by cholesterol: From molecular determinants to impact on arterial functionAlex M. Dopico, Anna N. Bukiya, and Kelsey C. North32. Clinical strategies for reducing cholesterol levelsClaude K. Lardinois and Samantha Karr33. Medicinal chemistry and pharmacology of statinsBob M. Moore, II and George A. Cook34. Cyclodextrins as promising therapeutics against cholesterol overload Florina Zakany, Tamas Kovacs, Lajos Szente, and Zoltan Varga35. Hyperlipidemia and rheumatoid arthritisAliki I. Venetsanopoulou, Paraskevi V. Voulgari, and Alexandros A. Drosos36. Management of hypercholesterolemia in individuals living with HIV/AIDSMusaab Ahmed, Marium Ahmed, Dushyant Mital, and Mohamed H Ahmed

Dr. Anna Bukiya’s PhD laboratory focuses on lipid modulation of ion channel function in excitable tissues and sensitivity to drugs. Dr. Bukiya’s work has been consistently funded by the NIH and private foundations, and she has published 43 original research articles, authored or co-authored 10 reviews, and 9 book chapters. Dr. Bukiya also co-edited two books and served as a sole editor on one book, all focused on the role of lipids in modulating protein function during normal physiology and pathological conditions. The Bukiya laboratory utilizes computational modelling of cholesterol-protein interactions, biochemical and fluorescence microscopy-based quantification of cellular cholesterol levels, rat models of high-cholesterol diet, and statin use to control cholesterol levels in vivo. Dr. Bukiya is a current member of several societies, including Biophysical Society, International Drug Abuse Research Society, and American Society for Pharmacology and Experimental Therapeutics. Dr. Alex Dopico MD, PhD received his M.D. from the University of Buenos Aires, specializing in arterial hypertension. Following his Ph.D. in Pharmacology, he conducted postdoctoral training at UMass Worcester focusing on the regulation of ion channels by lipids and alcohols. Over two decades, the Dopico laboratory has addressed ion channel regulation by a wide variety of lipids, including fatty acids, leukotrienes, glycerophospholipids, PIP2 and related phosphoinositides, bile acids and other cholanes, pregnenolone and cholesterol itself. His studies on alcohol and toluene aim at determining the relative contribution of ion channels and their surrounding membrane lipids to drug action, addressing the impact of drug action on organ function, with a focus on cerebral arteries. In 2009, he received a Merit Award from NIAAA for his work on ethanol actions on slo1 channels. He is member of the National Advisory Committee on Alcohol Abuse & Alcoholism.

Select Guide Rating

• Part 1. Cholesterol Chemistry and Cell Function1. Cholesterol chemistry, and laboratory synthesisHélio M.T. Albuquerque, Clementina M.M. Santos, and Artur M.S. Silva2. Molecular evolution of cholesterol and other higher sterols in relation to membrane structureOle G. Mouritsen3. Role of cholesterol in maintaining the physical properties of the plasma membraneWitold K. Subczynski, Marta Pasenkiewicz-Gierula, Justyna Widomska, and Natalia Stein4. The fundamental interaction of cholesterol with lipid membranes: The umbrella modelJuyang Huang5. Model peptides and cholesterolIstván P. Sugár and Parkson Lee-Gau Chong6. Cholesterol and ceramide: An unlikely pairAritz B. García-Arribas, Alicia Alonso, and Félix M. Goñi7. Cholesterol-recognizing amino acid consensus motifs in transmembrane proteins: Comparative analysis of in silico studies and structural dataFodil Azzaz, Henri Chahinian, Nouara Yahi, Coralie Di Scala, Carlos J. Baier, Francisco J. Barrantes, and Jacques Fantini8. Effects of cholesterol on the GPCR AT1 receptor and its interplay with AT1 antagonistsS. Kiriakidi, Z. Cournia, and T. Mavromoustakos9. Principles of cholesterol regulation of ion channelsQiu-Xing Jiang and Irena Levitan10. Fluorescent probes for microscopy visualization of cholesterol topography and dynamics in membranesFrancisco J. Barrantes11. Cholesterol transport in blood, lipoproteins, and cholesterol metabolismMark T Mc Auley and Amy E Morgan12. Common laboratory research methods for detection and quantification of cholesterolAnna N. Bukiya, Hanxuan Li, Steven Mysiewicz, and Wei LiPart 2. Cholesterol Homeostasis and its disruption14. Diet-induced hypercholesterolemia in small laboratory animal modelsTina Herfel15. Nutrition and cholesterol metabolismGhada A. Soliman16. Cholesterol and early developmentIsabella Ellinger and Waranya Chatuphonprasert17. Clinical and biochemical diagnostic methods: What do blood lipid levels tell us?Marshall B. Elam18. Familial hypobetalipoproteinemia and abetalipoproteinemiaFrancine K. Welty19. Critical illness and cholesterol levelsZdenek Zadak20. Familial hypercholesterolemiaShifa Jebari-Benslaiman, Unai Galicia-Garcia, Asier Larrea-Sebal, Kepa B. Uribe, Cesar Martin, and Asier Benito-Vicente21. Niemann-Pic type C disease (NPC)Agnieszka Ługowska22. Rare monogenic disorders of cholesterol metabolismMalgorzata Bednarska-Makaruk and Agnieszka Ługowska23. Secondary (acquired) hypercholesterolemiaArrigo F.G. Cicero and Ivan R. Cincione24. Blood lipids and molecular pathways of atherogenesisRicardo Stein, Filipe Ferrari, and Vítor M. Martins25. Lysosomal acid lipase: Roles in rare deficiency diseases, myeloid cell biology, innate immunity, and common neutral lipid diseasesGregory A. Grabowski and Hong Du26. Cholesterol and pathogensTatiana M. Clemente and Stacey D. Gilk27. Involvement of cholesterol and ß-amyloid in the initiation and progression of Alzheimer’s diseaseLuis G. Aguayo, Jorge P. Roa, Carlos F. Burgos, and Juliana  Gonzalez-Sanmiguel28. Cholesterol and alcoholAndrew S. Bell, Emma M. O’Connell, and Falk W. LohoffPart 3. Pharmacological Considerations and Perspectives29. Cholesterol stiffening of lipid membranes and drug interactions: Insights from neutron spin echo and deuterium NMR spectroscopySudipta Gupta, Fathima T. Doole, Teshani Kumarage, Milka Doktorova, George Khelashvili, Rana Ashkar, and Michael F. Brown30. Cholesterol in drug delivery systemsDanRong Hu and ZhiYong Qian31. Modification of vascular receptor pharmacology by cholesterol: From molecular determinants to impact on arterial functionAlex M. Dopico, Anna N. Bukiya, and Kelsey C. North32. Clinical strategies for reducing cholesterol levelsClaude K. Lardinois and Samantha Karr33. Medicinal chemistry and pharmacology of statinsBob M. Moore, II and George A. Cook34. Cyclodextrins as promising therapeutics against cholesterol overload Florina Zakany, Tamas Kovacs, Lajos Szente, and Zoltan Varga35. Hyperlipidemia and rheumatoid arthritisAliki I. Venetsanopoulou, Paraskevi V. Voulgari, and Alexandros A. Drosos36. Management of hypercholesterolemia in individuals living with HIV/AIDSMusaab Ahmed, Marium Ahmed, Dushyant Mital, and Mohamed H Ahmed